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Therapies that target the PD-1/B7-H1 axis have revolutionized cancer treatment, yet precise knowledge of how this pathway provides benefit continues to evolve. Here, we report a novel role for the immune checkpoint ligand B7-H1 in the accumulation of tissue-resident memory CD8
+
T-cells (TRM). After intracranial infection, Theiler's murine encephalomyelitis virus (TMEV) generates TRM that are maintained in the central nervous system (CNS) tissues of B7-H1
WT animals. Although no differences in acute T-cell responses between B7-H1
WT and B7-H1 KO are observed, at long-term periods post-infection the maintenance of CD8 + TRM is diminished in B7-H1 KO animals. This is accompanied by redistribution of the resident CD8 + population from primarily CD103 + TRM to a diminished population of TRM and a preponderance of non-specified PD-1
+ T-cells. T-cell transfer studies demonstrate that host B7-H1 is necessary for maintaining TRM and limiting accumulation of PD-1 + CD103 − CD8 + T-cells. The lack of host B7-H1 results in compromised control of a heterologous virus re-challenge demonstrating a functional defect in TRM mediated virus control. This study reveals a new role for B7-H1 in TRM and pro-inflammatory PD-1 + CD103 − CD8 + T-cell accumulation in the CNS and gives insight for using B7-H1/PD-1 blockade in modulating long-term T-cell protection.
Keywords: Theiler's murine encephalomyelitis virus, B7-h1, programmed death-1, cD8, tissue resident memory, picornaviruses, immune checkpoint, cTl, viruses inTrODUcTiOn The development of immunologic memory is a fundamental process in response to vaccination and is critical for protection from secondary exposure to viral pathogens. However, many questions regarding the establishment and maintenance of immunologic memory remain unanswered. Acute viral infections are often accompanied by the recruitment and expansion of cytotoxic effector CD8
+ T-cells that target MHC class I restricted viral antigens presented on the surface of infected cells. This targeting promotes killing of the infected cell and clearance of the virus from invaded tissues. Upon viral clearance, the CD8 + T-cell population contracts in a regulated process to avoid continuous immune mediated pathology and to restore tissue homeostasis. Although there is a substantial reduction of the effector CD8 + T-cell population, the CD8 + T-cells that remain persist and become long-term memory CD8 + T-cells (TM). Upon reexposure to pathogens, TM respond with increased potency and efficiency and rapidly clear secondary infections. These TM can be classified into subgroups based on their location, cell surface biomarker expression, and transcriptional profiles (1) . CD8 + central memory cells (TCM) and effector memory cells (TEM) remain within the lymphoid organs or in circulation and provide a rapid response that is activated upon antigen re-exposure (2) . In contrast, tissue resident memory CD8
+ T-cells (TRM) remain at sites of previous infection and provide tissue-specific protection from secondary exposure (3) . TRM have been identified in a variety of tissues, including lung, skin, intestine, and brain (4) (5) (6) (7) . The integrin CD103 has been shown to promote the retention of TRM in brain tissues (7) and interactions with ligands expressed in the brain may provide support for their maintenance and retention within the CNS. Although emphasis continues to be placed on the mechanisms involved in TCM and TEM development in lymphoid organs and circulating blood, more recently interest has grown in understanding tissue-specific TRM development, regulation, and maintenance (8) (9) (10) (11) (12) .
The expression of the immune checkpoint molecule B7-H1 (PD-L1) and interactions with its receptor programmed death-1 (PD-1) constitute a fundamental mechanism in regulating the magnitude of effector T-cell responses. This response is particularly critical after inflammatory viral infections and activation of CD8 + cytotoxic lymphocytes in vital host tissues. The upregulation of PD-1 on T-cells after activation and subsequent interaction with B7-H1 in host tissues ensures that a regulated process of T-cell contraction and elimination of unnecessary inflammation occurs (13) . In the presence of chronic antigen exposure, some CD8 + T-cells convert to an exhausted state, which coincides with their upregulation of PD-1 and the gradual loss of their ability to eliminate their intended targets (14) . These findings have formed the basis for the development of immunotherapeutic interventions aimed at targeting immune checkpoint molecules for the treatment of cancers (15) . Some effector CD8
+ T-cells that ultimately eliminate virus from infected tissues are downregulated yet are maintained as TRM for protection from subsequent re-exposure to pathogens. Although both exhausted CD8 + cells and TRM develop after viral infection, it is unclear how specific tissue interactions regulate the development of either of these CD8 T-cell phenotypes. Several factors unique to the responsive T-cell population, the host tissues or the virus have potential roles in the development of these persisting tissue specific T-cell populations.
Intracranial infection with the mouse pathogen Theiler's murine encephalomyelitis virus (TMEV) is often used as a model of persistent infection and neuropathology in mice expressing susceptible MHC class I alleles (16) . However, in mice expressing the H-2D b allele acute encephalitis and virus infection is cleared by an immunodominant CD8 + T-cell response to the virus antigen VP2121-130 (17) . Upon viral clearance, immune-mediated pathology subsides and replicating virus is no longer detected in the central nervous system (CNS). This clearance is preferentially associated with the H-2D b allele in C57BL/6 mice and H-2D b provides exclusive protection in FVB transgenic mice (18) . Although acute CD8 + T-cell responses to VP2121-130 comprise up to 70% of the central nervous system infiltrating lymphocyte (CNS-IL) pool of CD8 + T-cells, little is known about the development of brain-specific TRM after infection with this virus. Previously, others have shown a role for immune checkpoint molecule blockade in the protection of the CNS from persistent virus infection and chronic inflammation (19) . However, it is unclear what role B7-H1 may play in the generation of TRM after acute encephalitis and viral clearance. To that end, we examined the continued presence of TRM in the CNS at time points greater than 30 days post-TMEV infection using both B7-H1
WT and B7-H1 KO animals. We found that after the resolution of acute infection, T-cells responsive to the viral peptide VP2121-130 and to the embedded peptide antigen OVA257-264 developed into TRM and persisted within the CNS for longer than 200 days post-infection in the absence of replicating virus. Further, we identified a role for host B7-H1 in enhancing the accumulation of TRM in the CNS and demonstrated that, as a consequence of that role B7-H1 is required for controlling a secondary virus challenge. These findings have implications for the design and use of immune checkpoint blockade therapies and extend our understanding of the role B7-H1 plays in resolving CNS inflammation and of its contribution to the development of TRM.
MaTerials anD MeThODs animals and cell lines
C57BL/6 (B7-H1 WT ) and C57BL/6 CD45.1 (Ly5.1) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). OT-1 TCR (CD90.1 + ) transgenic mice were provided by T. Tian (Harvard University, Boston, MA, USA). B7-H1 KO C57BL/6 mice were provided by L. Chen (Yale University, New Haven, CT, USA). All animals were housed in the Mayo Clinic Department of Comparative Medicine and cared for according to the Mayo Clinic Institutional Animal Care and Use Committee and NIH guidelines for animal use and care. All biologic agents were used in accordance with the policies and guidelines designated by the Mayo Clinic Institutional Biosafety Committee.
antibodies and Tetramers
The antibodies used for flow cytometry were Brilliant Violet 421™ anti-mouse CD8α (Biolegend; Clone 53-6.7), APC/Cy7 anti-mouse CD8β Antibody (Biolegend; YTS156.7.7), Brilliant Violet 605™ anti-mouse CD45 (Biolegend; 30-F11), PerCP/Cy5.5 anti-mouse CD103 (Biolegend; 2E7), BV421 anti-Mouse CD103 (BD Biosciences; M290), PE-Cyanine7 anti-human/mouse CD44 (Tonbo; IM7), PE anti-mouse CD279/PD-1 (Tonbo; J43.l), FITC anti-mouse CD279/PD-1 (eBioscience; RMP1-30), FITC, antimouse CD69 (BD Biosciences; H1.2F3), and FITC anti-mouse CD90.1 (eBioscience; HIS51). Allophycocyanin labeled H-2D b / VP2121-130, H-2K b /SIYR, and H-2K b /OVA257-264 tetramers were kindly provided by Dr. Aaron Johnson (Mayo Clinic, Rochester, MN, USA) and were generated using previously described methods (17, 20) . Anti-PD1 hamster monoclonal antibody (G4) was purified and dosed as previously described (21) . intravascular labeling of CD8 + T-cells was PE anti-mouse CD8α (BD Biosciences; 53-6.7). Intravascular labeling of peripheral blood lymphocytes and CNS-IL was performed using previously described methods (22) .
cns-il isolation and Facs analysis
Isolation of CNS-ILs was performed using previously described methods (23) . Briefly, at designated time points, post-infection mice were euthanized with CO2 prior to collection of brain and spinal cord into 5 mL of 4°C RPMI. Animals were perfused with 50 mL of PBS prior to tissue harvest to exclude the possibility of contamination by blood-derived rather than tissue-derived cells. Tissues were then transferred to a Pyrex Ten Broeck homogenizer (Corning 7 mL, 0.15 mm gap) and homogenized until complete tissue dissociation is attained (5-7 strokes). The CNS homogenate was then sieved through a Corning™ 100 µm strainer (Fisher Scientific; Cat. No. 08-771-19) followed by addition of 5 mL RPMI. The homogenate was then brought to 70% Percoll prepared in PBS in a final volume of 30 mL prior to centrifugation in at 7,840 g for 25 min at 4°C. After centrifugation a top myelin debris layer was removed and isolated cells were resuspended in a total volume of 50 mL RPMI before pelleting at 800 g. Red blood cells were lysed with ACK (ammonium chloride potassium) lysing buffer, washed with RPMI, and resuspended in FACS buffer before addition of appropriate fluorochrome labeled antibodies or tetramers and analysis by FACS. Final stained cell populations were spiked with 50 µL of CountBright™ absolute counting beads prior to FACS to determine absolute cell numbers. Cells were run on a BD LSRII flow cytometer (BD Bioscience), and data were analyzed using FloJo Software version 7.6.5 (Tree Star, Ashland, OR, USA). For reinfection experiments mice were depleted of peripheral CD8 + cells by injection of 0.5 mg of anti-mouse CD8 antibody (Lyt2.43) on day 7, 5, and 3 prior to reinfection with GD7-KS1 as previously described (24) .
Virus, infection, and Quantitation
Molecularly defined viruses derived from the two TMEV subgroup viruses were used for these experiments. The XhoI-OVA8 virus is derived from the Daniel's strain which belongs to the less neurovirulent subgroup TO. The TMEV-GD7-KS1 virus is derived from the GDVII substrain that belongs to the highly neurovirulent subgroup GDVII (25) . The XhoI-OVA8 (TMEV-OVA8) and GD7-KS1 (TMEV-GD7) viruses were described previously (26, 27) . Mice were infected intraperitoneally with 2 × 10 6 or intracranially with 2 × 10 5 PFU of TMEV-OVA8. Virus titers were determined by plaque assay using NCTC clone 929 (L-929) cells (ATCC, Manassas, VA, USA) using a protocol described previously (28) . Semi-quantitative RT-PCR targeting the VP2 capsid protein of TMEV-OVA8 was used to determine virus RNA levels and has been described (27) .
In Vivo Killing assay
A modified version of a previously described technique was used to test in vivo killing by cytotoxic lymphocyte responses induced with TMEV-OVA8 (29) . On day 6 after intraperitoneal infection of B7-H1
WT or B7-H1 KO mice, three peptide-pulsed target cell populations were prepared from C57BL/6 CD45.1 donor splenocytes. Two concentrations of carboxyfluorescein succinimidyl ester (CFSE; Excitation/Emission 490 nm/520 nm) were used to label the no peptide population (CFSE Low ) and the virus peptide VP2121-130 (FHAGSLLVFM; CFSE High ). Chicken ovalbumen257-264 (SIINFEKL) pulsed splenocytes were labeled with a second dye PKH26 (Ex/Em; 551 nm/567 nm). The three populations were mixed at equal numbers before challenge of TMEV infected mice by intravenous injection. 2 × 10 7 total cells were injected per mouse. Percent killing was determined by relative number of cells recovered from the splenocytes of infected and naïve animals. Splenocytes were assessed by FACS for the number of cells having the CD45.1 marker and the distribution of the three labeled populations. Percent killing was determined using the following equation: % specific lysis = 1−[rnaive/rinfected] × 100 where: r = %CFSE low cells/%CFSE high or PKH26 labeled cells.
adoptive Transfer of OT-1 T-cells and Virus infection
CD8 + T-cells were purified from the spleens of OT-1 (Thy1.1 or Thy1.2) TCR transgenic mice or from OT-1 B7-H1KO mice (30) using magnetic bead separation (Miltinyi Biotec, Auburn, CA, USA). After isolation, 2 × 10 6 CD8 + cells were injected intravenously into B7-H1
WT or B7-H1 KO mice. On the day of transfer mice were infected intracranially with 2 × 10 5 PFU of TMEV-OVA8. At designated times, post-infection CNS tissues and spleens were harvested and processed for lymphocyte isolation prior to immunophenotyping by FACS.
statistics
Mean and SD values were calculated using Excel 2010. Statistical analysis was performed using Sigmaplot for Windows version 11.0. All parametric data were analyzed by t-test. Non-parametric data were analyzed by Rank-sum assay. Significance was determined by P < 0.05.
resUlTs intracranial infection with an attenuated TMeV Virus results in the accumulation and Maintenance of Tissue resident Memory cD8 + T-cells in the cns
Theiler's murine encephalomyelitis virus infection of the CNS generates an acute encephalomyelitis that is ultimately cleared by day 14 due to an immunodominant CD8 + T-cell response to the viral peptide VP2121-130 (18, 31) . The generation of this response and the activation of cytotoxic perforin expressing T-cells promotes viral clearance and subsequently inflammation resolves. To determine whether infection with TMEV generates CNS TRM, we infected C57BL/6 mice intraperitoneally or intracranially with TMEV-OVA8 and examined the accumulation of virus-specific memory CD8
+ T-cells 98 days post-infection. This attenuated TMEV virus generates strong CD8 + T-cell responses to a virus genome embedded OVA8 peptide as well as the endogenous immunodominant virus antigen VP2121-130 (27) . At 98 days post-infection, we isolated CNS-ILs and splenocytes from infected animals and found that virus specific H-2K b -OVA8 
were present in the CNS after intracranial infection, but not after intraperitoneal infection ( Figure 1A) . Recovered splenocytes from both intracranial and intraperitoneal infection generated a population of virus specific OVA8
+ T-cells, verifying that infection via both routes promotes the generation of antigen-specific (VP2 + ) CD8 + T cells ( Figure 1B ). Phenotypic analysis of total CD8
+ T-cells recovered from the CNS of infected animals revealed that all CD8
+ T-cells expressed high levels of CD44 (effector/memory T-cell marker) on day 6 but dimmer levels of CD44 at day 98, while CD44 levels were comparable between CD8
+ T-cells recovered from the spleen ( Figure 1C ).
Further analysis of OVA8
+ T-cells recovered from both the CNS and spleen demonstrated that the CNS derived virus specific CD8
+ T-cells expressed high levels of CD69 (T-cell activation marker) and CD103 (tissue-resident memory T-cell marker) compared to spleen derived OVA8 + cells ( Figure 1D ). These findings demonstrate that intracranial TMEV infection results in the development and maintenance of a long lived CNS CD103
B7-h1 Does not regulate acute cytotoxic T-cell Function or alter Virus clearance
To determine the role that B7-H1 plays in the development of virus specific cytotoxic T-cell responses we infected B7-H1 wild-type (B7-H1 WT ) and B7-H1 knockout mice (B7-H1 KO ) with TMEV-OVA8 for 6 days to determine whether immune responses induced by infection can kill virus specific target cells in an in vivo CTL assay. We found that the effector T-cells generated by B7-H1
WT or B7-H1 KO mice equivalently killed both VP2121-130 and OVA257-264 target cells (Figure 2A) . In addition, intracranial infection of B7-H1
WT and B7-H1 KO mice for 6 or 98 days demonstrated no difference in the level of TMEV RNA obtained from CNS tissues (Figure 2B) . A further analysis of CNS homogenates demonstrated that no replicating virus remains in the CNS of C57BL/6 mice after 34 days as assessed by plaque assay, a finding consistent with attenuation of this strain (27) and with previous investigations using intracranial infection with the DA strain of TMEV in C57BL/6 (H-2 b ) mice (32).
B7-h1 Promotes the retention of long-term Virus-specific T-cells in the cns
We next investigated the role of B7-H1 in the development and maintenance of virus specific CD8 + T cell responses in the CNS after intracranial infection with TMEV-OVA8. On day 6 postinfection, intracranial infection of either B7-H1 WT + T-cells recovered from B7-H1 KO mice at this acute time point this difference was not significant (p = 0.112) (Figures 3A-C) .
Long-term post-infection time points were further investigated to determine the role of B7-H1 in promoting the accumulation of virus-specific CD8 + T-cells. We found that the quantity of CD8
+ T-cells remaining in the CNS at 98 days post-infection was approximately 10% of that seen during acute infection in both B7-H1
WT and B7-H1 KO mice ( Figure 3C ). To further characterize the residual CD8 + T-cell population, we determined the percent and quantity of T-cells that were specific for the known virus specific epitopes. We found that the percentage of OVA8 + and VP2
+ T-cells recovered from the CNS of mice infected for 98 days was decreased in B7-H1 KO mice when compared to B7-H1 WT mice (Figures 3A,B) . In addition, a decrease in the absolute number of virus specific T-cells identified by both tetramers was observed for the CD8 + T-cell population in B7-H1 KO mice ( Figure 3C ). These findings suggest that B7-H1 plays a role in the long-term accumulation of TRM cells after intracranial virus infection.
B7-h1 influences the accumulation of
PD-1 + cD103 − cD8 + T-
cells in the cns
Although our finding suggests that B7-H1 plays a role in promoting CNS-TRM after virus infection, the absolute number of total CD8 + T-cells that remain in the CNS of mice infected for 98 days was increased in B7-H1 KO mice compared to B7-H1 WT ( Figure 3C ), suggesting that non-specified CD8 + T-cell populations fail to contract or are maintained in the CNS at this extended time point post-infection. To determine if phenotypic differences between non-specified and virus specific CD8 + T-cells existed, we examined the phenotype of the CNS resident CD8 + T-cell populations during acute infection and at 98 days post-infection in B7-H1
WT and B7-H1 KO mice. First, we assessed the expression levels of CD103 on CD8
+ T-cells recovered from the CNS of TMEV-OVA8 infected animals, a marker previously used to identify CNS TRM (7, 33) . During the acute inflammatory phase of infection, very few of the total CD8 + T-cells or the virus-specific VP2 + cells expressed the TRM marker CD103, and no differences in this marker were observed between B7-H1
WT and B7-H1 KO mice ( Figure 4A) . On day 98 post-infection, a majority of the total CD8 + T-cells recovered from the CNS of B7-H1 WT animals expressed high levels of CD103. In contrast, this population in B7-H1 KO animals was decreased and coincided with an enhanced population of CD8 + T-cells that expressed lower levels of CD103 ( Figure 4A) . Since the phenotypic expression of CD103 in the virus-specific CD8 + T-cells was comparable between B7-H1 WT and B7-H1 KO , it seems that the generation of virus-specific TRM was not necessarily influenced by B7-H1 expression. However, the decrease of virus-specific CD8 + T-cells in B7-H1 KO CNS-IL compared to the CD103 − CD8 + T-cell population ( Figure 3C ) suggests that the quality of the virus-specific TRM response and their accumulation in the CNS could be regulated directly by B7-H1 or indirectly by competing cells present in the absence of B7-H1 (Figure 4A) .
To investigate potential mechanisms for retention of CD103 − CD8 + T-cells in the absence of B7-H1, we measured their expression of PD-1, a ligand of B7-H1 identified as a marker for both regulatory T-cells and exhausted T-cells. Of interest, the CD103 − CD8 + T-cell population that accumulates in the CNS of B7-H1 KO mice expressed significantly higher levels of PD-1 compared to that of B7-H1
WT mice ( Figure 4B ). In contrast, total CD103
+ CD8 + T-cells and virus-specific VP2 + CD103 + TRM derived from the CNS and spleen of B7-H1
WT and B7-H1 KO mice expressed comparable but low levels of PD-1 ( Figure 4B ; Figure  S1A in Supplementary Material). Since PD-1 high CD103 − CD8
+ T-cells dramatically increased in the CNS of B7-H1 KO mice, it is possible that their accumulation is directly under the control of B7-H1 when present.
Since CD103 − CD8 + T-cells represent a population of T-cells that persist in the CNS from early acute infection through time points well beyond virus clearance, we investigated whether CD103 − CD8 + T-cells were pro-inflammatory cells that persist in the absence of B7-H1. We isolated CNS-IL from B7-H1 KO mice and restimulated them in vitro to assess the potential for secreting the pro-inflammatory cytokine IFNγ. We found that the nonspecific CD103
− CD8 + T-cells derived from the CNS of B7-H1 KO mice secreted IFNγ in response to polyclonal activation of T-cells using PMA/ionomycin ( Figure 4C ). Similar to a population of CD103 − CD8 + T-cells present in the spleen of previously infected B7-H1 KO mice ( Figure S1B in Supplementary Material). Taken together, our findings suggest that B7-H1 promotes the maintenance of PD-1 low CD103 + TRM by limiting the accumulation of pro-inflammatory PD-1 high CD103 − CD8 + T-cells. To verify that peripheral blood cells and intravascular lymphocytes do not contribute to the pool of CD8 + T-cells that are recovered from the CNS, we performed in vivo intravascular staining to discriminate circulating cells from tissue-resident lymphocytes in B7-H1 KO mice infected with TMEV-OVA8 greater than 90 days prior to testing. After a 3-min pulse with in vivo anti-CD8 antibody, whole peripheral blood and CNS-IL were harvested and analyzed by flow cytometry (Figure 4D) . We found that 97.8% of peripheral blood circulating CD8
+ cells were labeled with the intravascular CD8 antibody, whereas the CNS-IL-derived tissue resident CD8
+ cells had very few cells labeled by this approach (3.3%). This provides further evidence that the CD8 + cells derived by these methods are indeed resident T cells embedded within CNS tissues.
host specific B7-h1 influences T rM Maintenance in the cns Previously, we have shown that expression of B7-H1 on tissue or on T-cells can modulate the function of CD8 + T-cells (13, 34) . To determine the role of host tissue-specific B7-H1 expression on the regulation of CD8 + TRM, we transferred congenically marked wild-type OT-1 T-cells into B7-H1
WT or B7-H1 KO host animals prior to infection with TMEV-OVA8 ( Figure 5A ). After 6 days of infection, the percent and number of transferred OT-1 T-cells that infiltrated the CNS were comparable between B7-H1 WT and B7-H1 KO host mice (Figures 5B,C) . In addition, the endogenous virus-specific TRM cell percentages were comparable to those observed previously in B7-H1
WT and B7-H1 KO animals without adoptive transfer ( Figures S2A,B in Supplementary Material). On day 33 post-infection, the percentage and number of recovered OT-1 CD8
+ T-cells were lower in the CNS of B7-H1 KO mice compared to B7-H1 WT mice ( Figure 5B) . To verify the conversion of transferred OT-1 T-cells to TRM, we measured the levels of CD103 expression on OT-1 T-cells on day 6 and 33 post-infection. We found that the majority of OT-1 T-cells shifted from CD103 − at day 6 to CD103 + at day 33 ( Figure 5C ). In addition, the absolute number of CD103 + OT-1 TRM cells decreased in the absence of B7-H1, from 27,982 + 8,723 cells (mean + SD) in B7-H1 WT to 9,602 + 10,647 cells in B7-H1 KO (t-test, p = 0.017). Endogenous host CD8
+ T-cells increased in B7-H1 KO mice compared to B7-H1 WT ( Figure 5B) which was due to an increased number of non-specified CD103 − CD8 + T-cells ( Figures S2A,B in Supplementary Material). These results suggest that host-specific B7-H1 influences the accumulation of CD103 + TRM in the CNS post-TMEV infection.
To determine whether T-cell specific B7-H1 expression would affect the accumulation of TRM, we transferred OT-1 wildtype T-cells (OT-1 WT ) or B7-H1 deficient OT-1 CD8 + T-cells 
B7-h1 is required for Virus control upon secondary Brain infection
Since B7-H1 promotes the maintenance of TRM, we asked whether lack of B7-H1 would affect virus clearance in the CNS after secondary infection. To address this question, we used the highly pathogenic TMEV variant GD7-KS1 (TMEV-GD7) as a heterologous secondary CNS infection (26) , this TMEV variant contains genetic determinants known to increase neuropathology and is attributed to high pathogenicity and lethality even at low doses when injected directly into the CNS (25) . Although few cross neutralizing antibody epitopes have been defined, the neutralization profiles are unique (35) . Importantly, the immunodominant CD8 T-cell epitope VP2121-130 is conserved between TMEV-OVA8 (primary infection) and TMEV-GD7 (secondary infection), allowing direct assessment of virus specific TRM function in the CNS. We first infected B7-H1 WT and B7-H1 KO mice with TMEV-OVA8. Then to evaluate the potential protection from TRM on day 277 post-infection, we eliminated circulating CD8 + T-cells using an anti-CD8 depleting antibody. After CD8 T-cell depletion, the previously infected mice were re-infected intracranially with TMEV-GD7 ( Figure 6A) . Three days postchallenge CNS-IL and splenocytes were isolated from rechallenged mice to verify peripheral CD8 depletion and to determine the phenotype of CNS derived cells. 8 days after the final dose of CD8 depleting antibody and 3 days after virus rechallenge CD8 depletion was maintained with a 91.4 + 1.3% reduction in total CD8
+ T-cells in the spleen of B7-H1 WT mice and an 87 + 4.2% reduction in B7-H1 KO mice compared to non-depleted control ( Figure 6B) . CNS-IL were analyzed by flow cytometry to determine the phenotype of resident CD8
+ T-cells. Consistent with previous experiments, this cohort of B7-H1 KO mice had a reduced number of CD8
+ TRM compared to the B7-H1 WT group (Figure 6C) . Further, TMEV load was assessed from the CNS of B7-H1
WT and B7-H1 KO animals by analysis of viral RNA and replicating virus. The levels of TMEV RNA were comparable between the CNS of B7-H1 KO and B7-H1 WT mice (p = 0.164), suggesting viral RNA was present as either encapsidated functional virions or as residual viral transcripts present after virus inactivation. However, more plaque forming units were identified in the CNS of B7-H1 KO mice compared to B7-H1 WT mice (Figure 6D ), suggesting that host B7-H1 is required to promote protection from secondary CNS virus infection by promoting the accumulation of virus-specific CD8 + TRM in the CNS. + CNS-IL and the absolute number of CD8 + cells in the spleen was decreased in the PD-1 blockade group (Figure 7A) . By day 35; however, no difference in the percentage or absolute numbers of CD8 + or CD4 + cells were detected in the CNS of B7-H1 KO mice when comparing anti-PD-1-treated versus control IgG-treated animals. Decreases in the absolute numbers of CD8 + and CD4 + cells were observed in the spleen at day 35 in groups treated with anti-PD-1 compared to control IgG-treated group (Figure 7A) .
To further interrogate the CD8 + memory populations, we analyzed CD8 + VP2 + cells by flow cytometry to determine how PD-1 blockade influences the accumulation of virus-specific and non-specific CD8 + PD-1 + cells in the CNS and spleen. We found that the populations of PD-1 + cells in the CD8 + VP2 + and the CD8 + VP2 − subsets were significantly reduced using anti-PD-1 antibody demonstrating that PD-1 blockade reduces the CD8 + PD-1 + population in both the CNS and the spleen at the 6 day acute time point. After 35 days, the differences between the anti-PD-1 and control IgG groups resolve in the CNS and spleen ( Figure 7B) . Furthermore, the expression of the TRM marker CD103 is consistent with the retention of a CD103
− population of cells in the CNS of B7-H1 KO animals that is not influenced by systemic treatment with PD-1 blockade ( Figure 7C) . Of interest, the expression levels of PD-1 in the VP2 − populations in both treatment groups at day 35 were increased in relation to the VP2 + group suggesting that the accumulation of the CD8 + CD103
− PD-1 high population in the CNS was not influenced by PD-1 blockade (Figures 7B,C) . We hypothesize that the inability of the anti-PD-1 antibody to access the CNS through the blood-brain barrier may prevent therapeutic targeting of PD-1 expressing cells in the CNS.
DiscUssiOn
Although much attention has been focused on the generation of tissue resident memory T-cells (TRM) in protection from infection or cancer, less is known about how these cells accumulate in distinct niches throughout the body. In this study, we identified a novel role for the immune checkpoint ligand B7-H1 in the promotion of TRM accumulation in the CNS after intracranial viral infection with TMEV. We find that B7-H1 expression in host tissues is important for restricting the inflammatory PD-1 high
CD103
− CD8 + T-cells that limit TRM in the CNS. We found a deficit in the quality and quantity of virus-specific TRM in the CNS of B7-H1 deficient hosts after intracranial infection with TMEV, a virus that is ultimately cleared by CD8 + T-cell responses to virus antigens. Similarly, others have reported a reduction of TRM in the brain of B7-H1 KO mice following infection with the herpes virus murine cytomegalovirus (MCMV) (36) . Our findings suggest a new role for B7-H1 within the CNS which includes promotion of TRM maintenance through restriction of PD-1 high CD103 − CD8
+ T-cells that accumulate in the absence of B7-H1. The interaction of cell surface PD-1 expressed by CD8
+ T-cells with the PD-1 ligand B7-H1 is important for resolving CD8 + T-cell responses and preventing sustained immunopathology. One mechanism by which T cell responses are resolved is through the induction of T-cell apoptosis induced by PD-1 ligation in tissues that express B7-H1 (13) . Consistent with this hypothesis, we find that B7-H1 may be involved in the depletion of non-specified inflammatory PD-1 high CD8 + T-cells in the CNS following viral infection. One hallmark of these T-cells is high expression of PD-1, suggesting that in the absence of ligand B7-H1, inflammatory CD8 + T-cells with high levels of PD-1 would compete for long-term residence with virus-specific TRM in the CNS post-infection. Importantly, these PD-1 high CD8
+ T-cells may regulate the accumulation of virus-specific TRM. One potential hypothesis is that B7-H1 limits the accumulation and survival of low-affinity or antigen non-specific CD8 + T-cells following clearance of infections in order to provide space for tissue resident T-cells that are protective against secondary infections, a finding consistent with an associated regulatory function of PD-1 expressing cells (37) .
We found that the increased population of CD103 − CD8
+ T-cells observed in B7-H1 KO mice produced IFNγ upon stimulation. It is plausible that IFNγ produced by CD103
− pro-inflammatory T-cells suppressed the accumulation of TRM in B7-H1 KO mice. The role of IFNγ in suppression of memory CD8
+ T-cells has been reported in lung following influenza infection (38) . Although IFNγ does not directly inhibit T-cell proliferation, it suppresses memory T-cell generation through two processes, including the induction of activation-induced cell death of effector cells (39, 40) and through activation of T-bet and its subsequent inhibition of IL-7 receptor expression (41) . A consequence of IL-7 receptor signaling in T-cells is reduced levels of bcl-2, a prosurvival molecule needed for memory T-cell survival. Further, low expression of bcl-2 was observed in CD103 + TRM cells in the brain of B7-H1 KO mice following MCMV infection (36) . Together, these studies suggest that IFNγ produced by PD-1 high CD103 − proinflammatory T-cells may contribute to the decreased number of TRM in the CNS of B7-H1 KO mice. Future studies are warranted to determine how this unique population of PD-1 high inflammatory CD8 + T-cells modulates virus antigen-specific TRM. Previous studies have demonstrated that intracranial virus infection results in the accumulation and maintenance of a persistent population of activated CD8
+ T-cells that persist in the absence of continued virus replication (42). Bergmann et al. found that both antigen specific and non-specific cells accumulate in the CNS after virus clearance with limited cytolytic and proinflammatory activity (43) . Similarly, we identified two unique populations of CNS antigen-specific and -non-specific CD8 + T-cells that can be discriminated by their expression of PD-1. We find that both inflammatory non-specific PD-1 high CD8 T-cells and PD-1 low antigen-specific TRM were sensitive to the presence of B7-H1. Further, we found that the TRM within B7-H1
WT or B7-H1 KO CNS tissues express a low level of PD-1 compared to inflammatory PD-1 high CD103 − CD8 + T-cells. This finding suggests that the low level PD-1 expression may prevent TRM in the CNS from a strong engagement with B7-H1 that would lead to T-cell apoptosis or exhaustion. It is not clear why PD-1 levels are different in these two T-cell subsets, but cues within the tissue microenvironment along with TCR signals may differentially regulate PD-1 expression (44, 45) . It should be noted that stimulation through a strong T-cell receptor interaction may not be the only signal promoting PD-1 expression, since antigen-specific TRM express low levels of PD-1, while antigen-non-specific CD103 − CD8 + T-cells expressed higher levels of PD-1 compared to TRM after viral infection.
Although PD-1 has been proposed as a biomarker for exhausted CD8
+ T-cells that develop during chronic viral infections (14, 46, 47) , PD-1 expression per se does not always lead to T cell exhaustion and its absence is not necessary for the prevention of exhaustion (48) + T-cells that increases in B7-H1 deficient environments (49) . The similarities observed between the inflammatory CD8 + T-cells here and regulatory CD8 + T-cells warrants further investigation.
The development of immunity in vital organs must be carefully regulated to provide sufficient control from long lasting pathology and protection of tissues with limited renewal capacity. The regulation of B7-H1 expression in the brain and how it can affect the long-term accumulation of CD8 + T-cells has implications for studies of immune-mediated neurologic disease. Although baseline B7-H1 expression levels are thought to be low in the CNS, it is often upregulated after injury or infection (50) (51) (52) . Our study demonstrates that the level of B7-H1 expression in host tissues can determine the quality of the CD8 + T-cell population that occupies the CNS. Previous evidence demonstrates that brain resident CD8
+ T-cells accumulate with age (53) . However, it is unclear under what consequences these CD8
+ T-cells reach the brain and accumulate. One could speculate that over a lifetime, clinical or subclinical CNS infections and their associated inflammatory cascades could lead to an accumulation of CD8 + TRM in the brain and spinal cord. However, aging is also associated with deterioration of the blood brain barrier and an increase in immunosurvellance that allows CD8 + T-cells to enter the CNS under non-inflammatory conditions (54) . Nevertheless, both inflammatory and non-inflammatory mechanisms can promote the accumulation of TRM. Our findings here suggest that the level of B7-H1 expressed by host tissues can have consequences for the quality and quantity of the CD8 + T-cell subsets that accumulate within CNS tissues.
The discovery of immune checkpoints and the use of reagents that target these pathways have revolutionized cancer immunotherapy. However, their development and use in clinical trials for chronic viral infections or for long-term tumor control has been met with mixed success (55, 56) . Similarly here we find that PD-1antibody fails to deplete or influence the PD-1 high expressing CNS resident population of CD8 + cells or to enhance TRM accumulation. The major difference between targeting B7-H1/ PD-1 pathway in cancer and in viral infection is the cellular sources of B7-H1 or PD-1. In the tumor tissues, the blockade of PD-1/B7-H1 is mainly aimed at blocking the interaction between PD-1 + effector T cells and B7-H1 + tumor cells. However, in the infected tissues, since both effector and regulatory cells express PD-1, the net outcome of the blockade of PD-1/B7-H1 would be determined by a balance of the functions of effector cells and immune regulatory cells. To that end, our study identified a unique population of PD-1 high CD103 − CD8 + T-cells as a potential new cellular target of B7-H1/PD-1 therapy in chronic viral infections. However, since unique barriers exist in protected tissues like the CNS, the use of antibody based therapies will be challenging (57) . A prolonged blockade of B7-H1 or PD-1 may provide a risk for the accumulation of the inflammatory PD-1 high CD8 + T cells that eventually would impair the maintenance of protective TRM in particular tissues. To reduce the possibility of compromising long-term protection mediated by tissue resident CD8 + T cells, the timing and location of B7-H1/PD-1 blockade as a therapy for virus vaccines or infection should be carefully optimized in order to support the generation and maintenance of a pool of antigen specific CD8
+ TRM. In summary, our study reveals a new function of B7-H1 for the promotion of TRM maintenance by limiting the accumulation of inflammatory PD-1 high CD103 − CD8 + T cells in the CNS. This finding extends our understanding of the maintenance of TRM in the brain and provides new insights for optimizing B7-H1/PD-1 blockade to promote long-term protection from cancer or virus infection.
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